Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company covers events occurring on August 31, 2006, and September 1, 2006. The report details a significant legal victory regarding the patent protection of the drug PLAVIX and a subsequent adjustment to the company's financial guidance.
Key Financial Metrics and Material Changes
The filing does not provide specific revenue, profit, or cash flow figures for the period. However, it discloses the following material financial commitments and changes:
- Legal Bond Obligation: The company arranged for a surety bond of $200 million to secure a preliminary injunction against Apotex Inc. and Apotex Corp. regarding generic clopidogrel bisulfate.
- Collateral Requirement: The company pledged $200 million in cash collateral to secure its indemnity obligations to the surety provider (Travelers Casualty and Surety Company of America).
- Liability Sharing: Total court security is $400 million, shared 50-50 between Bristol-Myers Squibb and Sanofi-aventis.
- Guidance Revision: On September 1, 2006, the company announced a lowering of its previously disclosed full-year 2006 earnings per share guidance.
Outlook, Risks, and Management Commentary
Legal Outcome: The U.S. District Court for the Southern District of New York granted a preliminary injunction ordering Apotex to halt sales of a generic version of PLAVIX. This protects the market exclusivity of the product pending the final resolution of the patent litigation.
Financial Risks and Contingencies:
- Indemnity Liability: The company must indemnify the surety for any losses, costs, or damages if the court ultimately rules the injunction was wrongly imposed. This obligation is not contingent on rights against Sanofi.
- Credit Rating Triggers: The company may be required to provide additional credit support if its senior unsecured debt rating is downgraded below A by Standard & Poor's or A2 by Moody's, or if ratings are withdrawn.
- Earnings Outlook: Management has lowered full-year 2006 EPS guidance, though the specific revised figures are not detailed in this text.
Investor Verification Checklist
- Verify the specific revised full-year 2006 earnings per share guidance in the press release dated September 1, 2006 (Exhibit 99.2).
- Confirm the status of the $200 million cash collateral pledged and its impact on current liquidity.
- Monitor the company's credit ratings from Standard & P&R and Moody's to assess potential triggers for additional credit support.
- Review the terms of the 50-50 liability sharing agreement with Sanofi-aventis regarding the PLAVIX litigation.